Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia

The incidence of serum sickness following treatment of CLL with obinutuzumab has not been fully characterized, but is likely rare. Consideration should be given to this diagnosis in appropriate circumstances so that effective corticosteroid therapy can be initiated to alleviate inflammatory symptoms...

Descripción completa

Detalles Bibliográficos
Autores principales: Saba, Julie, Logan, Aaron C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457998/
https://www.ncbi.nlm.nih.gov/pubmed/28588833
http://dx.doi.org/10.1002/ccr3.969
_version_ 1783241659410022400
author Saba, Julie
Logan, Aaron C.
author_facet Saba, Julie
Logan, Aaron C.
author_sort Saba, Julie
collection PubMed
description The incidence of serum sickness following treatment of CLL with obinutuzumab has not been fully characterized, but is likely rare. Consideration should be given to this diagnosis in appropriate circumstances so that effective corticosteroid therapy can be initiated to alleviate inflammatory symptoms and organ dysfunction in a timely manner.
format Online
Article
Text
id pubmed-5457998
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54579982017-06-06 Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia Saba, Julie Logan, Aaron C. Clin Case Rep Case Reports The incidence of serum sickness following treatment of CLL with obinutuzumab has not been fully characterized, but is likely rare. Consideration should be given to this diagnosis in appropriate circumstances so that effective corticosteroid therapy can be initiated to alleviate inflammatory symptoms and organ dysfunction in a timely manner. John Wiley and Sons Inc. 2017-04-24 /pmc/articles/PMC5457998/ /pubmed/28588833 http://dx.doi.org/10.1002/ccr3.969 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Saba, Julie
Logan, Aaron C.
Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
title Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
title_full Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
title_fullStr Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
title_full_unstemmed Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
title_short Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
title_sort obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457998/
https://www.ncbi.nlm.nih.gov/pubmed/28588833
http://dx.doi.org/10.1002/ccr3.969
work_keys_str_mv AT sabajulie obinutuzumabinducedserumsicknessfollowingsalvagetherapyforchroniclymphocyticleukemia
AT loganaaronc obinutuzumabinducedserumsicknessfollowingsalvagetherapyforchroniclymphocyticleukemia

Ejemplares similares